Abstract: Objective To investigate clinical efficacy of Magnesium Isoglycyrrhizin on mixed drug-induced
liver injury (DILI), retrospectively. Methods A retrospective non-randomly case-control study was carried out
to analyze the clinical data of 60 patients who were diagnosed as mixed DILI in Qingdao Municipal Hospital
from January 2014 to December 2016. The patients were divided into two groups depending on therapeutic
regimens. Patients in control group were given conventional treatment such as liver protection, enzyme
degradation and jaundice and patients in treatment group were given Magnesium Isoglycyrrhizin (200 mg/d,
intravenous drip) on the basis of control group. The course of treatment was 4 weeks. Improvements of clinical
manifestations and liver biochemical markers were observed at 1 week, 2 weeks and 4 weeks, the clinical
efficacy of Magnesium Isoglycyrrhizin was also analyzed. Results After treatment, clinical symptoms and liver
biochemical markers improved significantly in both groups. The drop-out values of AST and ALT of patients in
treatment group were significantly higher than those of control group at 1 week (P ＜ 0.05). The drop-out values
of GGT were significantly higher than those of control group at 2 weeks (P ＜ 0.05) and the drop-out value of
ALP were significantly higher than that of control group at 4 weeks (t = 5.439, P ＜ 0.001). The total effective
rate in treatment group (93.75%) was significantly higher than that of control group (75.00%), with statistical
significance (t = 5.439, P ＜ 0.001). Conclusion Magnesium Isoglycyrrhizin is effective in the treatment of
mixed DILI through promoting AST, ALT, GGT and ALP.